Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.49 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.49 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2868312 | 0.98 | RAPGEF4 (0.53) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| SCHEMBL18905641 | 0.86 | TSHR (0.48) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| SCHEMBL8896899 | 0.84 | RAPGEF4 (0.67) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| SCHEMBL8221872 | 0.83 | GRIN2D (0.51) | RAPGEF4SIGMAR1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL16590399 | 0.83 | RAPGEF4 (0.51) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| SCHEMBL14345461 | 0.81 | RAPGEF4 (0.50) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| Ethylbenzene SCHEMBL11213271 | 0.81 | NPSR1 (0.53) | RAPGEF4MAPTSMN1; SMN2HPGDGAA | |
| SCHEMBL12707605 | 0.80 | TSHR (0.54) | MAPTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL21233397 | 0.80 | IDO1 (0.48) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B | |
| SCHEMBL11421191 | 0.80 | HDAC4 (0.54) | RAPGEF4SIGMAR1MAPTGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | claimed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-5489709-A | REACTING MONO-SUBSTITUTEED CYANAMIDE WITH A SECONDARY AMINE | CAMBRIDGE NEUROSCIENCE, INC. | 1996-02-06 | — | — | US | claimed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-0350166-B1 | Polymer compositions | NIPPON OIL CO LTD (JP) | 1994-03-23 | — | — | EP | disclosed |
| WO-1993019042-A1 | PREPARATION OF SUBSTITUTED GUANIDINES | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5120472-A | POLYMER COMPOSITIONS | NIPPON OIL COMPANY (JP) | 1992-06-09 | — | — | US | disclosed |
| US-4866162-A | Fiber-reactive fluoro-triazine containing dyestuff | CIBA-GEIGY CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
| US-4459186-A | Electrochemical oxidation of alkyl aromatic compounds | UOP INC. (US) | 1984-07-10 | — | — | US | disclosed |
| US-4302460-A | 4-Quinolinones having antihypertensive activity | THE BOOTS COMPANY LIMITED (GB) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | RAPGEF4 366/4885SIGMAR1 3518/4885MAPT 4206/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | RAPGEF4 4470/4885SIGMAR1 1253/4885MAPT 1761/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | RAPGEF4 366/4885SIGMAR1 3518/4885MAPT 4206/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | RAPGEF4 4690/4885SIGMAR1 1430/4885MAPT 3055/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | RAPGEF4 366/4885SIGMAR1 3518/4885MAPT 4206/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | RAPGEF4 4452/4885SIGMAR1 1194/4885MAPT 3274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.